← Leaderboards
Daniel Levy
Phoenix Pharmalabs, Inc.
$2,894,503
Attributed
$8,683,509
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2022–24$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
Funding mix
By agency
NIH$8,683,509 · 1
By mechanism
U01$8,683,509 · 1
Top collaborators
- Frances Rudnick Levin3 shared
- Lawrence R Toll3 shared
Most similar at Phoenix Pharmalabs, Inc.
Same institution · by research overlap
- Andrea Cippitelli$369,679
Others in their field
Other Rising Stars on “Code”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Daofeng Li · Salk Institute For Biological Studies$9,887,266
- Laura T Herriott · Carnegie Mellon University$6,279,999
- Fergal James Martin · University Of California Santa Cruz$5,992,279
Research focus
CodeAffinityAgonistAddictionAlcoholsAnalgesicsAnimalsAntagonistAlcohol Abuse TherapyAdme StudyBiologicalBiological AvailabilityBlood PressureBrainBuprenorphineBusinessesCardiovascular PhysiologyChronicCocaineAttenuatedCocaine Self-AdministrationBehaviorCocaine Use DisorderConstipation
Grant awards (3)
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$3,623,079
U01 · FY2024 · DA
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$2,380,269
U01 · FY2023 · DA
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder$2,680,161
U01 · FY2022 · DA